^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD276 expression

i
Other names: CD276, CD276 Molecule, CD276 Antigen, B7 Homolog 3, B7-H3, B7RP-2
Entrez ID:
Related biomarkers:
12h
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). (PubMed, Front Oncol)
Clinical trial results will be published in peer-reviewed journals. Trial registration numbers: ClinicalTrials.cov Registry (NCT05999396) and EU ClinicalTrials Registry (EU trial number 2022-503084-15-00).
P1 data • Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
|
CC-3
3d
PathoGraph: An Attention-Based Graph Neural Network Capable of Prognostication Based on CD276 Labelling of Malignant Glioma Cells. (PubMed, Cancers (Basel))
The graphs permit predicting individual patient survival on the basis of GSC community features. Our experiments lay a foundation for the use of the BCNN-abGCN tool chain in automated diagnostic prognostication using immunohistochemically labelled histological slides, but the method is essentially generic and potentially a widely usable tool in medical research and AI based healthcare applications.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
4d
CD276 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma through the TGF-β/SMAD signaling. (PubMed, Clin Exp Metastasis)
CD276 is significant upregulation in ESCC tissues and facilitates the EMT process in ESCC cells via the TGF-β/SMAD signaling, thus promoting the progression of ESCC.
Journal
|
CD276 (CD276 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD276 overexpression • CD276 expression • CD2 overexpression
8d
Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. (PubMed, J Cancer)
B7-H3 may stabilize EGFR to activate its downstream pathway for cancer cell proliferation and resistance to oxaliplatin (OXP)...Overall, these results showed that B7-H3 exhibited a high prevalence in COAD patients and was significantly associated with worse prognosis in COAD patients. Dual targeting of B7-H3 and EGFR signaling might be a potential therapeutic strategy for high-risk COAD patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
CD276 expression
|
oxaliplatin
11d
Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. (PubMed, Cancer Lett)
Favorable survival was observed only when HLA class I expression was high and B7-H3 expression low. Our results provide the rationale for targeting B7-H3 in patients with PDAC tumors displaying high HLA class I levels.
Journal
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • RELA (RELA Proto-Oncogene)
|
CD276 expression • CD8 expression
16d
A promising target for breast cancer: B7-H3. (PubMed, BMC Cancer)
Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint.In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.
Review • Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
21d
N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer. (PubMed, iScience)
Furthermore, rescue experiments demonstrated that reintroduction of B7-H3 considerably abolished the inhibitory effects on cell proliferation and invasion induced by silencing YTHDF1. Our results suggest that the YTHDF1-m6A-B7-H3 axis is crucial for CRC development and progression and may represent a potential therapeutic target for CRC treatment.
Journal
|
CD276 (CD276 Molecule) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
CD276 expression
1m
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. (PubMed, NPJ Breast Cancer)
In addition, patients with B7-H3 high and PD-L1 low expression showed the lowest anti-tumor immune infiltration, the highest collagen level, and the lowest therapeutic responses to multiple therapies, which mostly belong to armored-cold tumors. Overall, this research provides a novel subtyping strategy based on the combination of B7-H3/PD-L1 expression, which leads to a novel approach for the management of TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
|
PD-L1 expression • PD-L1 underexpression • CD276 expression • PD-L1-L
1m
High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis. (PubMed, Transl Oncol)
Mechanistically, B7-H3 enhanced the antiapoptotic ability of macrophage by up-regulating HIF-1ɑ via activating NF-κB. Taken together, these results imply that B7-H3 as a therapeutic target could hold promise for enhancing anti-tumor immune responses in individuals diagnosed with lung cancer.
Journal
|
CD276 (CD276 Molecule) • MIR29A (MicroRNA 29a)
|
CD276 expression
1m
Establishment of a pathomic-based machine learning model to predict CD276 (B7-H3) expression in colon cancer. (PubMed, Front Oncol)
We constructed a pathomics-based machine learning model for CD276 prediction directly from H&E-stained images in COAD. Through integrated analysis of the pathomic model and transcriptomics, the interpretability of the pathomic model provide a theoretical basis for further hypothesis and experimental research.
Journal • Machine learning
|
CD276 (CD276 Molecule)
|
CD276 expression
1m
Gastric cancer mesenchymal stem cells promote tumor glycolysis and chemoresistance by regulating B7H3 in gastric cancer cells. (PubMed, J Cell Biochem)
The therapeutic efficacy of oxaliplatin (OXA) and paclitaxel (PTX) was determined using CCK-8 and colony formation assays. This study shows that GCMSCs-CM derived TNF-α could upregulate the expression of B7H3 of GC cells to promote tumor chemoresistance. Our results provide a new basis for the treatment of GC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD276 (CD276 Molecule) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • CD276 expression • BAX expression
|
paclitaxel • oxaliplatin
2ms
B7-H3 promotes angiogenesis in rheumatoid arthritis. (PubMed, Mol Immunol)
B7-H3 modulates angiogenic activity in the joint synovium, demonstrating its therapeutic value in the context of RA.
Journal
|
CD276 (CD276 Molecule) • CD34 (CD34 molecule)
|
CD276 expression
2ms
Disruption of LPA-LPAR1 pathway results in lung tumor growth inhibition by downregulating B7-H3 expression in fibroblasts. (PubMed, Thorac Cancer)
The present study provided new insights for roles of LPA in CAFs, which could lead to the development of innovative therapies targeting CAFs in the TME. It is also reasonable to postulate a combinatory approach to treat malignant fibrous tumors (such as NSCLC) with LPAR1 antagonists and B7-H3 targeting therapies.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
3ms
The influence of the germline HSD3B1 adrenal-permissive variant (c.1100 C) on somatic alteration landscape, transcriptome, and immune-cell infiltration in prostate cancer. (ASCO-GU 2024)
The homozygous adrenal-permissive HSD3B1 variant (c.1100 CC) is associated with distinct tumoral features characterized by elevated AR signaling and MAPK activation. It is also associated with a unique immune-cell regulatory landscape, with higher B7-H3 expression, increased intratumoral dendritic cells and decreased immunosuppressive neutrophils. This distinct molecular landscape of HSD3B1 c.1100 CC–associated prostate cancers warrants special therapeutic considerations, including possibly using B7-H3–targeted therapies.
IO biomarker • Immune cell
|
ERG (ETS Transcription Factor ERG) • SPOP (Speckle Type BTB/POZ Protein) • FOXA1 (Forkhead Box A1) • TMPRSS2 (Transmembrane serine protease 2) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1) • KLK2 (Kallikrein-related peptidase 2) • HOXB13 (Homeobox B13)
|
CD276 expression • AR expression • AR splice variant 7 • SPOP mutation • TMPRSS2-ERG fusion • FOXA1 mutation • HOXB13 expression
3ms
CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate (ASH 2023)
Vobra duo showed robust in vitro cytolytic activity against CD276 positive AML cells highlighting the need for ongoing preclinical evaluations of CD276 targeted therapies in AML. Given the established safety profile for vobra duo this provides a clear path for rapid translation to clinical use for high risk AML patients.
Preclinical • IO biomarker
|
KMT2A (Lysine Methyltransferase 2A) • CD276 (CD276 Molecule) • CREBBP (CREB binding protein) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A)
|
CD276 overexpression • MLL rearrangement • CD276 expression • CBFA2T3 - GLIS2 fusion • MLL fusion
|
vobramitamab duocarmazine (MGC018)
3ms
COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma. (PubMed, BMC Gastroenterol)
Our research suggests that COL10A1 promotes pancreatic adenocarcinoma tumorigenesis by regulating CD276. This study provides new insight into biomarkers and possible targets for pancreatic cancer treatment.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
3ms
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. (PubMed, J Clin Invest)
Overall, biomarker-focused selection of models led to high efficacy of in vivo treatment. These data enable a paradigm shift to biomarker-driven trial designs for maximizing clinical benefit of ADC therapies.
Preclinical • Journal • Metastases
|
TP53 (Tumor protein P53) • AR (Androgen receptor) • RB1 (RB Transcriptional Corepressor 1) • CD276 (CD276 Molecule) • SLFN11 (Schlafen Family Member 11)
|
TP53 mutation • TP53 wild-type • AR positive • SLFN11 expression • CD276 expression • RB1 wild-type
3ms
B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy. (PubMed, J Cancer Res Clin Oncol)
Our findings demonstrated a correlation between B7-H3 expression and CD47 expression in GC patient tissues. Co-expression of B7-H3 and CD47 can serve as an indicator of poor prognosis in GC patients. In GC tumor tissue, but not adjacent tissue, B7-H3 and CD47 expression was accompanied with macrophage infiltration.
Journal • IO biomarker
|
CD276 (CD276 Molecule) • CD47 (CD47 Molecule) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD68 (CD68 Molecule) • CD86 (CD86 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD276 expression • CD47 expression • CD47 positive • CD68 positive
4ms
Analysis of immunosuppressive myeloid cells in the glioblastoma tumor microenvironment reveals therapeutically targetable immunomodulatory signals across populations. (SNO 2023)
These findings underscore the diversity of immunomodulatory signaling in the tumor-associated myeloid cell compartment, emphasizing the challenges in developing single-target immune checkpoint inhibitor therapy in GBM. Nevertheless, this data points to some common patterns of expression across major immunomodulatory cell populations that remain understudied in GBM and could herald more promising avenues of immunotherapy development.
Clinical • IO biomarker • Immunomodulating
|
CD276 (CD276 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • VSIR (V-Set Immunoregulatory Receptor)
|
CD276 expression
4ms
Targeting a shared glioblastoma cell state through adaptive Natural Killer cells augmented with Trispecific Killer cell Engager (TriKE) immune-modulator against CD276 (SNO 2023)
Our results suggest that a therapeutic strategy combining intra-tumoral injections of NK cells and a B7H3 specific TriKE holds promise and warrants clinical trial consideration.
IO biomarker • Trispecific
|
CD276 (CD276 Molecule) • IL15 (Interleukin 15)
|
CD276 expression
4ms
Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3. (PubMed, Nucl Med Biol)
[Tc]Tc-SYNT-179 provided the strongest improvement of tumour-to-organ ratios. Thus, affinity maturation of B7-H3 Affibody molecules could improve biodistribution and targeting properties for imaging of B7-H3-expressing tumours.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
4ms
Value of B7-H3 Expression as a Predictor of Response to Neoadjuvant Chemotherapy in Urothelial Cell Carcinoma of Bladder (SUO 2023)
Low level of B7-H3 expression on TURBT specimen is a predictor of complete pathologic response to neoadjuvant chemotherapy in UCB.
Clinical
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
4ms
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors suggesting potential anti-B7-H3 therapy in triple-negative breast cancer (SABCS 2023)
Multiple anti-B7-H3 therapies has been raised, such as DS-7300, MGA271, MGD009, and B7-H3 chimeric antigen receptor T-cell immunotherapy (CAR-T)...In the durvalumab-dependent cohort, paclitaxel-dependent cohort, anthracycline-dependent cohort, and our recruited NAT cohort, the B7-H3highPDL1low subgroup exhibited the lowest therapeutic response. Overall, this research provides a novel subtyping strategy based on the combination of B7-H3/PD-L1 expression that could potentially be applied to predict the therapeutic responses in TNBC, and suggests a potential biomarker-guided anti-B7-H3 therapy. Based on the classifier, we can select potential beneficiaries to deliver personalized medical services.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
PD-L1 expression • CD276 expression • PD-L1-L
|
Imfinzi (durvalumab) • paclitaxel • ifinatamab deruxtecan (DS-7300) • enoblituzumab (MGA271) • orlotamab (MGD009)
4ms
Deciphering pregnancy-associated breast cancer: distinctive molecular profile and clinical implications from GEICAM/2017-07 EMBARCAM study (SABCS 2023)
Our study shows that PABC is potentially a clinical and molecular different entity with predominance of the basal-like subtype. Moreover, our results suggest the activation of oncogenic pathways related to cell proliferation, DNA damage repair and p53 mutations which may lead to a clinically more aggressive phenotype for PABC patients. Likewise, the enrichment of BRCAness and HRD signatures found in PABC patients in our study may suggest an increased genetic instability due to a breakdown in the DNA damage repair.
Clinical • PARP Biomarker • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • CD276 (CD276 Molecule) • CDK4 (Cyclin-dependent kinase 4) • CCNA2 (Cyclin A2) • TGFB1 (Transforming Growth Factor Beta 1) • CDC20 (Cell Division Cycle 20) • FAM83D (Family With Sequence Similarity 83 Member D) • TRIP13 (Thyroid Hormone Receptor Interactor 13) • CDK3 (Cyclin Dependent Kinase 3) • KIF2C (Kinesin Family Member 2C) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
|
HER-2 positive • TP53 mutation • HR positive • HER-2 negative • HER-2 expression • HRD • CD276 expression • HR positive + HER-2 negative • ER expression • ER overexpression • HRD signature • PTEN mutation + HR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • nCounter® Breast Cancer 360™ Panel
4ms
Determination of PDK1, SLC2A1, EGFR, PTEN, CD276 Gene Expression Levels and IDH1 Gene R132H Polymorphism in Brain Tumor Tissues. (PubMed, Turk Neurosurg)
We obtained similar findings for previously reported PDK1, EGFR, PTEN, and CD276 gene expression levels. In contrast, SLC2A1 expression was markedly downregulated, as reported in other tumor studies. These findings may be due to the unique nature of brain tumor tissues. Additionally, a decrease in PTEN gene expression has been observed in grade IV brain tumors, including glioblastoma and meningioma. Although the size of the analyzed study group was limited, the gene expression results showed similarities in the behavior of genes during cancer staging.
Journal
|
EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD276 (CD276 Molecule) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
EGFR expression • IDH1 R132H • PTEN expression • CD276 expression • IDH1 R132
4ms
B7-H3/CD276 and small-cell lung cancer: What's new? (PubMed, Transl Oncol)
The addition of an anti-PD-L1, atezolizumab or durvalumab, to platinum/etoposide regimen became the standard of care for first-line therapy of extensive-stage (ES)-SCLC with the 12 months median survival exceeded for the first time. The most promising preliminary clinical results have been reported by DS7300a and HS-20093, both are antibody-drug conjugates, that are under investigation in ongoing trials for the treatment of pretreated SCLC. This review will provide an overview of B7-H3 and corresponding inhibitors and the clinical development in the management of SCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • etoposide IV • ifinatamab deruxtecan (DS-7300) • HS-20093
5ms
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. (PubMed, J Immunother Cancer)
Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models and represents a potential candidate for clinical translation.
Preclinical • Journal
|
CD276 (CD276 Molecule) • ANXA5 (Annexin A5)
|
CD276 expression
|
temozolomide • topotecan • vobramitamab duocarmazine (MGC018)
5ms
A Fc-optimized B7-H3 antibody for induction of NK cell reactivity against acute myeloid leukemia (SITC 2023)
Target cell-restricted lysis of AML cell lines and primary AML patients’ samples by 8H8-SDIE was potently induced in Europium and FACS-based cytotoxicity assays, while iso-SDIE treatment did not induce lysis of leukemic cells. Conclusions Taken together, we here introduce a novel attractive immunotherapeutic compound potently inducing NK cell anti-leukemic reactivity as a beneficial treatment option for AML.
IO biomarker
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B)
|
CD276 expression • IL2RA expression
5ms
A novel B7H3×4–1BB bispecific antibody for solid tumor treatment (SITC 2023)
Conclusions HK056–001, a B7H3×4–1BB bsAb with human IgG1 Fc fragment prevents tumor development by killing tumor cells directly via effector functions mediated by NK and cytotoxic T cells. These results indicate that this bsAb holds the potential to be developed as a novel clinical therapy for cancer types with B7H3 expression.
IO biomarker
|
IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
CD276 expression • IFNG expression
5ms
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies (SITC 2023)
Finally, we showed that B7-H3 inhibition combined with blockade of PD-L1 or Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) achieved durable anti-tumor effects and had curative potential in PTEN/TP53-deficient CRPC model. Conclusions Given that B7-H3 targeted therapies have been evaluated in early clinical trials, our studies provide new insights into the potential of biomarker-driven combinatorial immunotherapy targeting B7-H3 in prostate cancer, among other malignancies.
PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
CD276 expression
5ms
A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors (SITC 2023)
Exploratory objectives include analysis of intratumoral and peripheral PD, including markers of T-cell activation; expression of tumor/immune markers; ctDNA levels; and association of PK and/or PD with clinical outcome. Enrollment has begun.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD276 (CD276 Molecule) • CD28 (CD28 Molecule)
|
CD276 expression
|
Keytruda (pembrolizumab)
5ms
Anti-B7H3 chimeric antigen receptor NK cells for high-risk pediatric brain tumors (SITC 2023)
Targeting pediatric brain tumors with an anti-B7H3 CAR-NK cell therapy may provide a safe and effective treatment for patients who have extremely limited therapeutic options. As B7-H3 is a tumor associated antigen found to be overexpressed in a large variety of tumor types, this strategy may also be useful for treatment of other B7-H3 expressing cancers.
Clinical • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD276 (CD276 Molecule)
|
MYC amplification • CD276 expression
6ms
Lateral interactions between CD276 and CD147 are essential for stemness in breast cancer: a novel insight from proximal proteome analysis. (PubMed, Sci Rep)
Furthermore, we compared CSCs to non-CSCs to identify CSC-specific cell-surface membrane proteins that are closely interact with CD147 and revealed that lateral interaction between CD147 and CD276 concealed within the lipid raft microdomain in CSCs, confers resistance to docetaxel, a commonly used chemotherapy agent for various cancer types, including metastatic breast cancer...Subsequent immunohistochemical analysis in independent cohorts of HER2+ BC support for the association between co-expression of CD147 and CD276 and a poor response to chemotherapy. Collectively, our study suggests that the lateral interaction between CD147 and its proximal partners, such as CD276, may serve as a poor prognostic factor in BC and a predictive marker for the critical phenotypic determinant of BC stemness.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD276 (CD276 Molecule) • BSG (Basigin (Ok Blood Group))
|
HER-2 expression • CD276 expression
|
docetaxel
6ms
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
P1/2, N=25, Recruiting, Dushu Lake Hospital Affiliated to Soochow University
New P1/2 trial
|
IL6 (Interleukin 6) • CD276 (CD276 Molecule) • IL10 (Interleukin 10)
|
CD276 expression
|
QH104
6ms
B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway. (PubMed, Chin Med J (Engl))
B7-H3 has a regulatory effect on GC stemness and the regulatory effect is achieved through the AKT/Nrf2/GSH pathway. Inhibiting B7-H3 expression may be a new therapeutic strategy against GC.
Journal
|
CD276 (CD276 Molecule) • CD44 (CD44 Molecule)
|
CD276 overexpression • CD276 expression • CD44 expression
6ms
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors. (PubMed, Cancer Cell Int)
Our preclinical data indicate that ITC-6102RO is a promising therapeutic agent for B7-H3-targeted therapy. Moreover, we anticipate that OHPAS linkers will serve as a valuable platform for developing novel ADCs targeting a wide range of targets.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
7ms
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (clinicaltrials.gov)
P1, N=32, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
CD276 (CD276 Molecule)
|
CD276 expression
|
cyclophosphamide • fludarabine IV • B7-H3 CAR-T
7ms
Retrospective data • Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
7ms
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study (ESMO 2023)
B7-H3 expression was moderate to high in most patients; no correlation was observed between response and B7-H3 level, and an update will be presented at the congress. Table: 690P Efficacy Conclusions I-DXd continues to demonstrate a manageable safety profile and promising antitumor activity with encouraging DOR and OS in these heavily pretreated patients, which warrants further clinical evaluation across multiple indications.
Clinical • P1/2 data • Metastases
|
CD276 (CD276 Molecule)
|
CD276 expression
|
ifinatamab deruxtecan (DS-7300)
7ms
Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study (IASLC-WCLC 2023)
I-DXd demonstrated robust and durable efficacy in this subset of patients with heavily pretreated SCLC. Likewise, it was tolerable with manageable toxicity. A phase 2 study (NCT05280470) of patients with second- or third-line extensive stage SCLC only is currently ongoing.
Clinical • P1/2 data • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
|
ifinatamab deruxtecan (DS-7300)